Melanoma vaccines

Current Opinion in Oncology

Volumn 12, Issue 2, 2000, Pages 163-173

  Brinckerhoff, Laurence H ^a   Thompson, Lee W ^a   Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GANGLIOSIDE GM2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELANOMA VACCINE; TUMOR CELL VACCINE; TUMOR VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; MELANOMA; PRIORITY JOURNAL; REVIEW; VACCINATION;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; MELANOMA; SKIN NEOPLASMS; VACCINATION; VACCINES, DNA;

EID: 0034502332     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200003000-00012     Document Type: Review

References (142)

1. A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man
2. Update on active specific immunotherapy with melanoma vaccines
3. Human tumor immunotherapy: New opportunities as well as new challenges
4. Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients
5. Cancer vaccines '98: A reductionistic approach
6. Cancer vaccines
7. Cancer statistics, 1997
8. Cutaneous melanoma
9. A prospective evaluation of a triple-drug regimen containing cisplatinum, vinblastine, dacarbazine (CVD) for metastatic melanoma
10. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
11. Active specific T-cell-based immunotherapy for cancer: Nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects
12. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
13. Developing recombinant and synthetic vaccines for the treatment of melanoma
14. Type 1 versus type 2 cytokine release by VB T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
15. A pathogenic role of the Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma
16. A conditioned dendritic-cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
17. Antityrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy
18. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients
19. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
20. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax
21. Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccines
22. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
23. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies
24. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
25. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
26. Ganglioside vaccines with emphasis on GM2
27. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
28. T cell defined tumor antigens
29. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
30. Vaccination with IL-7 gene modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase 1 study
31. Phase I study to the immunotherapy of metastatic malignant melanoma by cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene
32. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
33. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogenic melanoma cells. A phase I-II study
34. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases
35. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
36. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development
37. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification
38. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
39. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
40. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
41. Identification of a peptide recognized by five melanoma-specific human cytotoxic t cell lines
42. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
43. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
44. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
45. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection
46. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100
47. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells
48. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
49. A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
50. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes
51. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
52. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
53. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
54. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
55. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and HLA-A33
56. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
57. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
58. Generation of xenogeneic cytotoxic T cells from peptides derived from the her-2/neu protooncogene
59. Association of HER2/neu expression with sensitivity to tumor-specific CTL in Human ovarian cancer
60. Ovarian and breast tumor-associated t lymphocytes stimulated with an antigenic peptide derived from her2/neu show enhanced cytotoxicity against autologous tumor
61. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
62. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
63. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
64. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
65. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
66. Autologous cytolytic T lymphocytes recognize a mage-1 nonapeptide on melanomas expressing HLA-Cw*1601
67. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
68. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
69. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
70. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3
71. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
72. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
73. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
74. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanoma is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
75. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
76. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients
77. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes
78. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
79. The peptide recognized by HLA-A68.2-restricted squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene
80. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
81. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
82. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1
83. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
84. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
85. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
86. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo
87. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine
88. Heat-shock proteins and the immune response
89. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
90. Transient expression of interleukin 2 receptors. Consequences for T cell growth
91. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells
92. Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF)
93. NK susceptibility varies inversely with target cell class I HLA antigen expression
94. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens
95. Tumor surveillance: Missing peptides and MHC molecules
96. Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial
97. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
98. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
99. Recombinant human granulocyte macrophage-colony stimulating factor(rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma
100. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
101. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo
102. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines
103. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice
104. Immunotherapy of cancer with dendritic-cell-based vaccines
105. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
106. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
107. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generales potent antitumor immunity in patients with metastatic melanoma
108. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
109. Dendritic cell vaccines for cancer immunotherapy
110. Vaccination with recombinant vaccinia virus encoding "self antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
111. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17
112. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
113. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
114. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector
115. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes
116. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
117. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function
118. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
119. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphoctes: Evidence for shared tumor antigens
120. Melanomas with concordant loss of multiple melanocytic differentiation proteins: Immune escape that may be overcome by targeting unique or undefined antigens
121. Perspectives on the role of MHC antigens in normal and malignant cell development
122. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer
123. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation
124. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
125. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
126. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes
127. Identification of human cancers deficient in antigen processing
128. Defective presentation of endogenous antigens by a murine sarcoma Implications for the failure of an anti-tumor immune response
129. Molecular characterization of defective antigen processing in human prostate cancer
130. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes
131. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with down regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
132. Melanoma cell expression of fas (Apo-1/CD95) ligand: Implications for tumor immune escape
133. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
134. Inverse relationship of melanocytic differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
135. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
136. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2
137. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma
138. Modifications of CD8+ T cell function during in vivo memory or tolerance induction
139. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1
140. Increased interleukin-10 serum levels in patients with solid tumours
141. Tumor antigens and tumor vaccines: Peptides as immunogens (Table 1)
142. Clinical implications of the new biology in the development of melanoma vaccines